Betta Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN

P/E

90.75

P/S

7.68

EPS

0.73

Div Yield, %

0.31%

Shrs. gr., 5y

0.55%

Rev. gr., 5y

14.05%

Revenues

3.61b

+24.81%

Net income

305m

-24.15%

CFO

911m

+0.01%

Dividend

Jun 17, 20250.19893 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Betta Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of oncology treatments. Among its key offerings are Icotinib hydrochloride, an orally taken epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and Ensartinib hydrochloride, an anaplastic lymphoma kinase (ALK) inhibitor, both utilized in the management of non-small-cell lung cancer. Founded in 2003, the firm is headquartered in Hangzhou, China.

URL

https://www.bettapharma.com/

IPO date

Nov 07, 2016

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT